Orphenadrine vs. Cyclobenzaprine: Muscle Relaxant Comparison for PI Cases

Amar Lunagaria — Co-Founder & Chief Pharmacist, LienScripts | March 4, 2026 | 8 min read

Orphenadrine (Norflex) and cyclobenzaprine (Flexeril) are both centrally acting muscle relaxants prescribed for post-traumatic muscle spasm, but they differ in mechanism, side effect profile, and what their presence in pharmacy records signals about the treating physician's clinical reasoning.

Orphenadrine (Norflex) is a centrally acting muscle relaxant with anticholinergic and mild analgesic properties, while cyclobenzaprine (Flexeril) is a structurally tricyclic muscle relaxant that is the most commonly prescribed skeletal muscle relaxant in personal injury cases. When orphenadrine appears in a PI pharmacy record instead of or alongside cyclobenzaprine, it signals a specific clinical rationale that attorneys should understand when evaluating case complexity.

• Cyclobenzaprine is the most commonly prescribed muscle relaxant in PI cases, FDA-approved for short-term treatment of acute musculoskeletal spasm
• Orphenadrine has both muscle relaxant and mild analgesic properties, providing dual benefit in post-traumatic pain with spasm
• Both are centrally acting but work through different pharmacological pathways
• Neither drug is a DEA-scheduled controlled substance
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report documenting the clinical rationale for muscle relaxant selection, including transitions between agents

Mechanism of Action

Cyclobenzaprine acts centrally in the brainstem to reduce tonic somatic motor activity, relieving skeletal muscle spasm without directly affecting muscle function. It is structurally related to tricyclic antidepressants (amitriptyline) and shares their anticholinergic and sedative properties. Cyclobenzaprine does not act at the neuromuscular junction or directly on skeletal muscle — it reduces muscle spasm through central nervous system depression of motor activity.

Orphenadrine also acts centrally but through a different mechanism. It has anticholinergic (antimuscarinic) activity that contributes to its muscle relaxant effect, and it also provides mild analgesic properties independent of its muscle relaxant action. Some evidence suggests orphenadrine may have NMDA receptor antagonist activity, which could contribute to pain modulation. Orphenadrine is also available in a combination product with aspirin and caffeine (Norgesic), providing multimodal therapy.

Side-by-Side Comparison

Clinical Significance for Personal Injury

Cyclobenzaprine in the PI pharmacy record is the default expectation. It is the most prescribed muscle relaxant in the United States and the standard first-line choice for acute muscle spasm following motor vehicle accidents, slip-and-fall injuries, and workplace trauma. Its presence is clinically unremarkable and expected in most PI cases involving musculoskeletal injury.

Orphenadrine appearing in the pharmacy record signals a more deliberate prescribing decision. Physicians may select orphenadrine over cyclobenzaprine for several reasons. First, orphenadrine's mild analgesic properties provide dual benefit — muscle relaxation plus pain relief — which can reduce the total number of medications the patient needs. Second, orphenadrine produces less sedation than cyclobenzaprine, which is important for patients who need to function during the day, maintain employment, or drive. Third, some patients who develop intolerable drowsiness on cyclobenzaprine are transitioned to orphenadrine for its better tolerability profile.

A pharmacy record showing cyclobenzaprine followed by orphenadrine documents a treatment transition that the treating physician determined was clinically necessary — either due to inadequate efficacy, intolerable sedation, or a clinical preference for orphenadrine's dual-action profile.

When Physicians Choose One Over the Other

Physicians select cyclobenzaprine when:

• Acute muscle spasm is the primary complaint and standard first-line therapy is appropriate
• Short-term treatment (2-3 weeks per FDA label) is anticipated
• The physician wants maximum muscle relaxation even at the cost of significant sedation
• Nighttime dosing is the primary goal (cyclobenzaprine's sedation can aid sleep)

Physicians select orphenadrine when:

• The patient needs muscle relaxation without excessive daytime sedation
• The mild analgesic property provides additional clinical value alongside spasm relief
• The patient did not tolerate cyclobenzaprine due to drowsiness or cognitive impairment
• The physician prefers a twice-daily dosing schedule for medication compliance
• The patient requires injectable muscle relaxant therapy (orphenadrine is available IV/IM)

As Amar Lunagaria, PharmD, LienScripts' Chief Pharmacist explains, "Orphenadrine is often the muscle relaxant of choice when the physician is optimizing for function — the patient needs spasm relief but also needs to remain alert enough to participate in physical therapy, maintain daily activities, or continue working with restrictions. This prescribing choice documents that the injury is affecting the patient's functional capacity."

Pharmacy Lien Documentation

Neither orphenadrine nor cyclobenzaprine is a DEA-controlled substance, so they do not carry the same prescribing restrictions as opioids. However, both generate lien-eligible dispensing records that document the ongoing clinical need for muscle relaxation therapy. Extended prescribing of either drug beyond the initial acute phase (past 4-6 weeks) documents persistent or recurrent muscle spasm — evidence that the injury has not fully resolved.

For more on muscle relaxants in PI, see Muscle Relaxant Comparison for Injury Cases. For information on orphenadrine specifically, read Orphenadrine (Norflex) as a Muscle Relaxant in PI Cases.